{
  "id": "5c6641ea7c78d69471000016",
  "type": "summary",
  "question": "What is the mechanism of action of tucatinib?",
  "ideal_answer": "Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29772459",
    "http://www.ncbi.nlm.nih.gov/pubmed/28923217",
    "http://www.ncbi.nlm.nih.gov/pubmed/29804905",
    "http://www.ncbi.nlm.nih.gov/pubmed/29955792"
  ],
  "snippets": [
    {
      "text": "In this article we review the role of currently available or investigational HER2 tyrosine kinase inhibitors: lapatinib, neratinib, afatinib and tucatinib in the treatment of brain metastases in HER2-positive breast cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29772459",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well tolerated new treatment option for patients whose disease has progressed on currently available therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29804905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The utility of human epidermal growth factor 2 (HER2)-directed therapies-lapatinib, ado-trastuzumab emtansine (T-DM1), neratinib and tucatinib-is also being studied in this setting. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28923217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29955792",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nTucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well tolerated new treatment option for patients whose disease has progressed on currently available therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29804905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29955792",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well tolerated new treatment option for patients whose disease has progressed on currently available therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29804905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The utility of human epidermal growth factor 2 (HER2)-directed therapies-lapatinib, ado-trastuzumab emtansine (T-DM1), neratinib and tucatinib-is also being studied in this setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28923217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer.<br><b>Objective</b>: To determine the maximum tolerated dosage of tucatinib in combination with T-DM1 in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.<br><b>Design, Setting, and Participants</b>: In this phase 1b open-label, multicenter, clinical trial, 57 participants enrolled between January 22, 2014, and June 22, 2015, were 18 years of age or older with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29955792",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}